IMMX · CIK 0001873835 · operating
Immix Biopharma is a clinical-stage biopharmaceutical company developing chimeric antigen receptor (CAR) cell therapies for light chain amyloidosis and immune-mediated diseases. The company's lead program is NXC-201, which targets relapsed or refractory AL amyloidosis. Additionally, Immix is advancing IMX-110, a program being evaluated in combination with the anti-PD-1 agent Tislelizumab under a clinical collaboration and supply agreement with BeiGene Ltd. for a Phase 1b trial in solid tumors.
The company operates as a clinical-stage entity with no disclosed revenue streams, relying on capital raises to fund development activities. Immix maintains a lean operational structure with 18 full-time employees and is headquartered in Los Angeles, California, with research activities extending to Australia.
Incorporated in Delaware in 2012, Immix is publicly traded on the Nasdaq exchange with a market capitalization of approximately $0.4 billion. The company's pipeline remains focused on cell therapy applications within niche disease areas.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-0.76 | $-0.76 | +14.6% | |
| 2023 | $-0.89 | $-0.89 | -50.8% | |
| 2022 | — | $-0.59 | — | |
| 2021 | — | — | — |